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Malignant melanomas were found in 15.8% of xeroderma 
pigmentosum (XP) patients with skin cancer in Japan. When 
multiple cancers were scored separately depending on the 
histopathologic types, 12.1 % of the skin cancers in XP pa­
tients was malignant melanoma. The relative incidence of 
malignant melanoma in skin cancer in XP patients is similar 
to that in skin cancer in general (12.6%), reported previously. 
Most of the malignant melanoma in XP patients developed in 
skin exposed to sunlight, in contrast to the high incidence of 
malignant melanoma in general in the unexposed skin of 
Japanese people. A DNA repair defect of UV damage is 
strongly suggested to be responsible for the high incidence of 
X eroderma pigmentosum (XP) is an autosomal reces­sive disease characterized by solar sensitivity of the skin and by the predisposition for developing skin cancer. Xeroderma pigmentosum has been known to be associated with DNA repair deficiency, and the 
high incidence of skin cancer in patients has been attributed to it. 
Most skin cancers are assumed to be caused by exposure to sunlight. 
Malignant melanoma in Japanese non-xeroderma pigmentosum pa­
tients are, however, most often found in areas not exposed to sun­
light. We have examined the skin cancers of 262 xeroderma pig­
mentosum patients in Japan in regard to their cellular DNA repair 
characteristics [1]. Eighteen malignant melanomas were recorded in 
these patients. All of them, except one, developed in skin exposed to 
sunlight. Possible involvement of DNA repair deficiency in skin 
cancer development will be discussed in this report. Evidence which 
may support the somatic mutation theory of carcinogenesis will be 
presented by our findings on mutagenesis in xeroderma pigmento­
sum cells. 
MATERIALS AND METHODS 
Clinical Records The records of the patients at their first visits 
were reported to the authors in most of the cases. This survey covers 
mainly university hospitals in Japan; some of the patients had visited 
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skin cancer in XP patients. The onset of malignant mela­
noma in XP patients was about ten years old, and was as early 
as those of basal cell carcinoma and squamous cell carcinoma 
in the patients with very low DNA repair capacities. Among 
nine genetic complementation groups and a variant type, 
group A XP cells were found to be extremely hypermutable 
by ultraviolet light, while group C XP cells were also hyper­
mutable, but at the same level as normal cells when adjusted 
for survival. Mutagenesis as a possible mechanism of carcino­
genesis in XP is supported by these results, but evidence in 
other cancer-prone hereditary diseases is yet to be obtained. 
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other clinics before they came to the university clinics. Earlier 
records of these patients were not usually available. The ages of the 
patients in the tables refer to those where biopsy samples were 
taken, except where otherwise specified as the ages or onset of skin 
cancer. Many of the patients have been followed by their doctors 
and additional data have been reported to the authors. All tumors 
were histopathologically examined either by the dermatologists or 
pathologists. Questionnaires were sent to the doctors when the 
information was not sufficient to be included in this survey. A total 
of 262 xeroderma pigmentosum patients with confirmed clinical 
records, as well as DNA repair data in their cells, are included in this 
survey. 
DNA Repair Tests Fibroblast cells were grown from the biopsy 
samples of all patients. Standard procedure was to grow the cells in 
Dulbecco's modified Eagle's minimum essential medium supple­
mented by 15% fetal bovine serum. Because the cell cultures were 
done in many laboratories encompassing the period of nearly 20 
years, culture conditions might be different in some cases. DNA 
repair tests were, however, carried out by the standardized method 
in most cases. Fibroblast cells were irradiated by ultraviolet light 
(predominantly 254 nm) from germicidal lamps followed by incu­
bation with methyl(3]H-thymidine (1 !lCi/ml) in the culture me­
dium for 2 to 3 h. Cells were fixed and processed for autoradiogra­
phy, as described previously [2]. The number of silver grains per 
nucleus was recorded, and the relative numbers of the grains in XP 
cells and in normal cells were taken as the unscheduled DNA syn­
thesis capacities. 
Mutation Lymphoblastoid cells transformed by Epstein-Barr 
virus were used for mutation studies. Results on mutation were 
published previously and are referred to in this article mainly for 
discussion; detailed procedures may be found elsewhere. 
RESULTS AND DISCUSSION 
Malignant Melanoma and Other Skin Cancers in XP Pa­
tients Table I gives the age distribution of XP patients with 
known DNA repair capacities which were measured by the relative 
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Table I. Age Distribution of Xeroderma Pigmentosum Patients 
with Malignant Melanoma in Relation to DNA Repair Capacity 
DNA Repair in UDS' (% of Normal Cells) 
Age �5 6-30 31-60 60� Total 
0-9 
10-19 
20-29 
30-39 
40-49 
50� 
Total 
4 
1 
5 
1 
2 
4 
1 
2 
3 
3 
9 
• UDS: Unscheduled DNA synthesis after UV irradiation as measured by 
autoradiography. 
5 
3 
2 
2 
3 
3 
18 
amount of unscheduled DNA synthesis (UDS) after UV irradiation 
of the cultured cells originating from the patients. Although the 
total number of patients (18) was small, the anatomical distribution 
was very similar to that of the skin cancer in 262 XP patients com­
piled by us [1]. Patients with low DNA repair capacities appear to 
develop malignant melanoma at a much earlier age than those with 
higher repair capacities. This strongly suggests that DNA repair 
deficiency is responsible for the development of malignant mela­
noma, as well as other skin cancers in XP patients. This hypothesis 
was further confirmed by the age of onset of malignant melanoma 
(MM), basal cell carcinoma (BCe), and squamous cell carcinoma 
(SCe) in XP patients as shown in Table II. XP patients with very 
low DNA repair capacities in their cells, complementation groups A 
and C, and unidentified patients having DNA repair capacities simi­
lar to group A patients, develop skin cancers by ten years of age on 
the average, while the age of onset of skin cancer in patients with 
higher DNA repair capacities occurs much later. It should be noted 
that the ages of onset for three histopathologic types of skin cancers 
are essentially similar except for malignant melanoma in patients 
with other intermediate levels of unscheduled DNA synthesis, sug­
gesting that the enhancement of carcinogenesis by the repair defi­
ciency is similar for these three types of cancer. 
Relative incidence of malignant melanoma in skin cancer in XP 
patients was 15.8%, as shown in Table III. If multiple skin cancers 
of different histopathologic types were scored separately as one for a 
type, malignant melanoma consisted of 12.1 % of all skin cancer in 
XP patients. This was almost equal to the relative fraction of malig­
nant melanoma in skin cancer in general in Japan, as surveyed by 
Tada and Miki [3]. Skin cancers in Japan, except for those in XP 
patients, are usually not multiple and almost all multiple skin 
cancers of different histopathologic types were found in XP pa­
tients. There were 31 XP patients with multiple skin cancers of 
different histopathologic types. Among them, 11 developed malig­
nant melanoma, two with basal cell carcinoma, two with squamous 
cell carcinoma, and seven with both basal and squamous cell carci­
noma. 
Table II. Age of Onset of Skin Cancer in Xeroderma 
Pigmentosum Patients in Relation to DNA Repair Capacity and 
Genetic Complementation Group 
Age of Onset (yr) and 
Number of Patients' 
Group BCC SCC MM 
A and 5% or less UDSb 9.3 (35) 8.2 (20) 7.5 (5) 
C 9.7 (3) 8.3 (33) 11.0 (2) 
Other Intermediate Levels 
of UDS' 40.9 (14) 43.3 (12) 14.0 (2) 
Variant and 60% < UDS 40.8 (30) 42.0 (14) 46.8 (9) 
• Number of patients in parentheses. 
• A and C are genetic complementation groups. 
, UDS: Relative amount of unscheduled DNA synthesis after UV in percent of 
normal cells. 
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Table III. Frequency of Malignant Melanoma in XP Patients 
Among XP patients in Japan 
Frequency in skin cancer in XP Patients 
Frequency in skin cancer in Japanese 
Among XP patients in China 
• Reference 3. 
6.9% (18/262) 
15.8% (18/114) 
12.6% (256/2027)' 
7.9% (6/77) 
Comparative studies on XP patients in Japan and China have 
been carried out in cooperation with Dr. Z.S. Jiang [4] and other 
colleagues in China. Seventy-seven XP patients were recorded; six 
developed malignant melanoma (Table III). The frequencies of 
malignant melanoma in XP patients in Japan and China may be 
much lower than that in Caucasian XP patients [5], although no 
exact frequency has been reported for the latter. 
The types and locations of malignant melanoma in XP patients in 
Japan (Table IV) indicate that they were caused mainly by sunlight 
exposure. Lentigo maligna melanoma is presumably caused by sun 
exposure and is found more often than other types. It is interesting 
to note that one melanoma in the eyeball was found in an unexposed 
area. It was one of six cancers found in organs other than skin in XP 
patients in Japan [6]. 
Because relatively few XP patients in Japan developed malignant 
melanoma, it may be reasonable to confine our discussion to the 
relationship between the incidence of malignant melanoma and 
genetic complementation groups in future studies. Group F XP 
patients, however, may be worth mentioning for their low risk of 
melanoma development; this group has been essentially limited to 
Japanese so far. Ten out of 11 group F patients have been reported 
from Japan, and three have developed skin cancers, but so far no 
malignant melanoma has been recorded [1]. 
Mutagenesis in XP Cells as a Possible Mechanism of Carcino­
genesis Correlation between high incidence of skin cancer by 
ultraviolet light in XP patients and hyper mutability ofXp cells by 
ultraviolet light provides support for the somatic mutation theory of 
carcinogenesis [7]. We have reported that XP cells belonging to 
complementation group A are extremely hypermutable by UV in 
inducing 6-thioguanine (6TG) resistance [8]. They are far more 
mutable than group C cells, which are also more mutable than 
normal cells. When frequency of mutation was plotted against sur­
vival of the cells by UV, XP group C cells overlapped with normal 
cells suggesting that damage leading to both killing and mutation 
were repaired in normal cells, but not repaired in XP group C cells. 
In XP group A cells, frequency of mutation was much higher than 
normal and XP C cells against cell survival. This may imply that the 
DNA repair process, which is defective in XP A cells, could be 
different from that in group C cells. XP A cells may have an addi­
tional defect in repairing UV damage in DNA, which leads to 
mutation but not to the killing of the cells. 
The ages of onset of skin cancer in XP A and C were approxi­
mately the same as shown in Table II. This appears to contradict the 
difference in mutability between XP A and C cells, although the 
number ofxp C patients was only three and therefore too small to 
Table IV. Types and Locations of Malignant Melanoma in XP 
Patients' 
Types and Locations Number of cases 
Nodular melanoma in exposed areas 2 
Lentigo maligna melanoma in exposed areas 9b 
Eyeball: conjunctiva 1 
unexposed area 1 
Lymph Node, mediastinal (Metastasis) 1 
Type unknownc 6 
• In addition to the 18 cases from Table I. two more cases without UDS data have 
been added. 
b One case had lentigo maligna melanoma in an unexposed area. 
, Five cases in exposed areas, one case in an unexposed area (metastasis ?). 
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Table V. Predisposed Susceptibility to Cancer and Mutation' 
Disease 
Xeroderma pigmentosum (XP) 
Ataxia telangiectasia (AT) 
Bloom's syndrome (BS) 
Fanconi's anemia (FA) 
Familial polyposis coli 
Down's syndrome 
Werner's syndrome 
Cancer 
+++b 
+++ 
+++ 
+++ 
+++ 
+ 
+ 
Mutation (Agent, reference) 
+++ (UV, Chemicals, 8, 9, to) 
- (Gamma-rays', 11) 
+4 (Spontaneous, 12) 
+++ (Diepozybutane, 13) 
+ (MNNG, 4NQO<) 
-/ (UV, x-rays 14) 
+ (Spontaneous, 15) 
• For mutation in XP and FA, negative (-) data are not shown. 
• +++: hypermutable. 
, Less than normal when adjusted for survival. 
J +: higher than normal. 
, M. Miyaki (personal communication). 
f -: same as normal. 
establish the characteristics of this group. However, if this is correct, 
mutability as an indication of carcinogenicity should require more 
precise analysis of underlying mechanisms. 
Genetic Predisposition to Cancer-Proneness Thus far, XP is 
the only example of the positive correlation between carcinogenesis 
and mutagenesis by the same agent. Table V summarizes the current 
status of the relationship between the predisposition to cancer and 
mutation. As discussed in the preceding sections, skin cancer of XP 
patients definitely appears to be caused by sunlight or exposure to 
ultraviolet light. Hypermutability ofXP cells by UV corresponds to 
UV carcinogenesis, and the similarity in the mechanisms of carcino­
genesis and mutagenesis is strongly suggested. Other diseases with 
increase susceptibilities to cancer are shown in Table V. The causes 
of cancer or carcinogenic agents for cancer in the patients with these 
diseases, however, have not been clearly identified. If we can iden­
tify the agents which are more mutagenic to the cells originating 
from the patients than to those of normal origin, these agents could 
be the cause of carcinogens is for these patients. 
Ataxia telangiectasia (AT) cells are sensitive to ionizing radiation 
[16], but were not hypermutable by gamma rays [11]. This suggests 
either that ionizing radiation or radiation-mimetic agents are not 
the cause of cancer in AT patients, or that the yield of mutation 
detected by conventional markers such as 6-thioguanine resistance 
could be different from the cancer-causing mutation, such as muta­
tion in oncogenes. Recently we found tht Fanconi's anemia (FA) 
cells were hypermutable by diepoxybutane, a DNA cross-linking 
agent [13]. Although DNA cross-linking agents are rare in the 
natural environments, they might be causing the high incidence of 
cancer in FA patients. These approaches are an extension of XP 
studies in our laboratory on the relationship between carcinogenesis 
and mutagenesis. One difficulty in the study of such diseases is the 
lack of knowledge of the underlying mechanisms in diseases other 
than XP. Involvement of DNA repair defects has been suggested in 
some of the diseases, but clear evidence has not yet been shown. 
In conclusion, xeroderma pigmentosum serves as the best exam­
ple of the relationship between DNA repair defects and cancer 
proneness. The high incidnce of malignant melanoma and other 
skin cancers in XP patients is best explained by a mechanism involv­
ing the DNA repair defect. 
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